Prostate cancer: Is it time to expand the research focus to early-life exposures?

Nature Reviews Cancer

Volumn 13, Issue 3, 2013, Pages 208-218

  Sutcliffe, Siobhan ^a   Colditz, Graham A ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEX HORMONE;

BODY HEIGHT; CANCER RISK; DIET; EARLY LIFE STRESS; ENVIRONMENTAL EXPOSURE; HISTOPATHOLOGY; HUMAN; LIFESPAN; MEDICAL RESEARCH; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PUBERTY; REVIEW; SEXUAL BEHAVIOR;

ENVIRONMENTAL EXPOSURE; HUMANS; LIFE STYLE; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84875421047     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3434     Document Type: Review

References (168)

1. American Cancer Society. Global Cancer Facts & Figures 2nd edn (American Cancer Society, 2011).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
3. Gronberg, H. Prostate cancer epidemiology. Lancet 361, 859-864 (2003).
4. Kim, S. T. et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate 70, 1729-1738 (2010).
5. Hsing, A. W., Tsao, L. & Devesa, S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60-67 (2000).
6. Lippman, S. M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51 (2009).
7. Gaziano, J. M. et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 301, 52-62 (2009).
8. Humphrey, P. A. in Prostate Pathology 2-29 (American Society for Clinical Pathology, 2003).
9. Marshall, W. A. & Tanner, J. M. in Human Growth: Postnatal Growth, Neurobiology (eds Falkner, F. & Tanner, J. M.) 171-209 (Plennum, 1986).
10. Ross, R. et al. Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst. 76, 45-48 (1986).
11. Rotkin, I. D. Studies in the epidemiology of prostatic cancer: expanded sampling. Cancer Treat. Rep. 61, 173-180 (1977).
12. Andersson, S. O. et al. Early life risk factors for prostate cancer: a population-based case-control study in Sweden. Cancer Epidemiol. Biomarkers Prev. 4, 187-192 (1995).
13. Chodosh, L. A. et al. Mammary gland development, reproductive history, and breast cancer risk. Cancer Res 59, 1765s-1772s (1999).
14. United Nations Scientific Committee on the Effects of Atomic Radiation. Effects of Ionizing Radiation. UNSCEAR 2006 Report. Vol 1 (2008).
15. Radiation Effects Research Foundation. A Cooperative Japan-US Research Organization. [online], http://www. rerf.or.jp/library/dl-e/lss14.html (2012).
16. Diamandis, E. P. & Yu, H. Does prostate cancer start at puberty? J. Clin. Lab. Anal. 10, 468-469 (1996).
17. Gardner, W. A. Jr & Culberson, D. E. Atrophy and proliferation in the young adult prostate. J. Urol. 137, 53-56 (1987).
18. De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nature Rev. Cancer 7, 256-269 (2007).
19. Jackson, M. A. et al. Factors involved in the high incidence of prostatic cancer among American blacks. Prog. Clin. Biol. Res. 53, 111-132 (1981).
20. Sakr, W. A., Haas, G. P., Cassin, B. F., Pontes, J. E. & Crissman, J. D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150, 379-385 (1993).
21. Sakr, W. A. et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8, 439-443 (1994).
22. Gu, F. L., Xia, T. L. & Kong, X. T. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China. Urology 44, 688-691 (1994).
23. Sanchez-Chapado, M., Olmedilla, G., Cabeza, M., Donat, E. & Ruiz, A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 54, 238-247 (2003).
24. Yin, M., Bastacky, S., Chandran, U., Becich, M. J. & Dhir, R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J. Urol. 179, 892-895 (2008).
25. Humphrey, P. A. in Prostate Pathology 226-257 (American Society for Clinical Pathology, 2003).
26. Nomura, A. M. & Kolonel, L. N. Prostate cancer: a current perspective. Epidemiol. Rev. 13, 200-227 (1991).
27. Preston, D. M. et al. Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 56, 812-816 (2000).
28. Whittemore, A. S., Cirillo, P. M., Feldman, D. & Cohn, B. A. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J. Urol. 174, 872-876 (2005).
29. Oesterling, J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145, 907-923 (1991).
30. Lee, Y. S. & Shanmugaratnam, K. Latent prostate carcinoma in Singapore Chinese. Singapore Med. J. 13, 1-6 (1972).
31. Shiraishi, T. et al. The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo 8, 445-447 (1994).
32. Miller, G. J., Pfister, S., Xia, T. & Zhau, H. E. Latent carcinomas of the prostate in males from Beijing. J. Urol. 151, A204 (1994).
33. Magi-Galluzzi, C. et al. The prevalence and extent of autopsy prostate cancer is less in South East Asian men than North American men. J. Urol. 171, 118 (2004).
34. Soos, G. et al. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur. Urol. 48, 739-744 (2005).
35. Stamatiou, K., Alevizos, A., Agapitos, E. & Sofras, F. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study. Prostate 66, 1319-1328 (2006).
36. Sutcliffe, S. et al. Prostate-specific antigen concentration in young men: new estimates and review of the literature. BJU Int. 110,1627-1635 (2012).
37. Lilja, H. et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117, 1210-1219 (2011).
38. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute Surveillance Epidemiology and End Results [online], http://seer.cancer.gov/ csr/1975-2009-pops09/ (2012).
39. Fang, J. et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58, 411-416 (2001).
40. Antenor, J. A., Han, M., Roehl, K. A., Nadler, R. B. & Catalona, W. J. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J. Urol. 172, 90-93 (2004).
41. Connolly, D., Black, A., Gavin, A., Keane, P. F. & Murray, L. J. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol. Biomarkers Prev. 17, 271-278 (2008).
42. Holmstrom, B. et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 339, b3537 (2009).
43. Tang, P. et al. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J. Urol. 183, 946-950 (2010).
44. Orsted, D. D., Nordestgaard, B. G., Jensen, G. B., Schnohr, P. & Bojesen, S. E. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur. Urol. 61, 865-874 (2011).
45. Kuller, L. H., Thomas, A., Grandits, G. & Neaton, J. D. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13, 373-377 (2004).
46. Breslow, N. et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer 20, 680-688 (1977).
47. Yatani, R. et al. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 29, 611-616 (1982).
48. Billis, A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology 28, 324-329 (1986).
49. Miller, G. J. in Advanced Therapy of Prostate Disease (eds Resnick, M. I. & Thompson, I. M.) 18-27 (B. C. Decker, 2000).
50. Whittemore, A. S., Keller, J. B. & Betensky, R. Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J. Natl Cancer Inst. 83, 1231-1235 (1991).
51. Polednak, A. P. College athletics, body size, and cancer mortality. Cancer 38, 382-387 (1976).
52. Whittemore, A. S., Paffenbarger, R. S. Jr., Anderson, K. & Lee, J. E. Early precursors of urogenital cancers in former college men. J. Urol. 132, 1256-1261 (1984).
53. Engeland, A., Tretli, S. & Bjorge, T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br. J. Cancer 89, 1237-1242 (2003).
54. Galobardes, B., Davey Smith, G., Jeffreys, M., Kinra, S. & McCarron, P. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am. J. Epidemiol. 161, 1094-1101 (2005).
55. van der Pols, J. C. et al. Childhood dairy intake and adult cancer risk: 65-y follow-up of the Boyd Orr cohort. Am. J. Clin. Nutr. 86, 1722-1729 (2007).
56. Locke, F. B. & King, H. Cancer mortality risk among Japanese in the United States. J. Natl Cancer Inst. 65, 1149-1156 (1980).
57. King, H. & Locke, F. B. Cancer mortality among Chinese in the United States. J. Natl Cancer Inst. 65, 1141-1148 (1980).
58. Kolonel, L. N. Cancer patterns of four ethnic groups in Hawaii. J. Natl Cancer Inst. 65, 1127-1139 (1980).
59. Severson, R. K., Nomura, A. M., Grove, J. S. & Stemmermann, G. N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 49, 1857-1860 (1989).
60. Singh, G. K. & Miller, B. A. Health, life expectancy, and mortality patterns among immigrant populations in the United States. Can. J. Public Health 95, I14-121 (2004).
61. Parkin, D. M. et al. Cancer in Jewish migrants to Israel. Int. J. Cancer 45, 614-621 (1990).
62. Tyczynski, J., Tarkowski, W., Parkin, D. M. & Zatonski, W. Cancer mortality among Polish migrants to Australia. Eur J Cancer 30A, 478-484 (1994).
63. Whittemore, A. S. et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl Cancer Inst. 87, 652-661 (1995).
64. McCredie, M., Williams, S. & Coates, M. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975-1995. Br. J. Cancer 79, 1277-1282 (1999).
65. Beiki, O., Ekbom, A., Allebeck, P. & Moradi, T. Risk of prostate cancer among Swedish-born and foreign-born men in Sweden, 1961-2004. Int. J. Cancer 124, 1941-1953 (2009).
66. Armstrong, B. K., Woodings, T. L., Stenhouse, N. S. & McCall, M. G. Mortality from Cancer in Migrants to Australia, 1962 to 1971. (The University of Western Australia, 1983).
67. Shimizu, H. et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63, 963-966 (1991).
68. McCredie, M., Williams, S. & Coates, M. Cancer mortality in migrants from the British Isles and continental Europe to New South Wales, Australia, 1975-1995. Int. J. Cancer 83, 179-185 (1999).
69. Gunnell, D. et al. Height, leg length, and cancer risk: a systematic review. Epidemiol. Rev. 23, 313-342 (2001).
70. Norgan, N. G. & Cameron, N. The accuracy of body weight and height recall in middle-aged men. Int. J. Obes. Relat. Metab. Disord. 24, 1695-1698 (2000).
71. MacInnis, R. J. & English, D. R. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17, 989-1003 (2006).
72. Lango Allen, H. et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467, 832-838 (2010).
73. Roddam, A. W., Allen, N. E., Appleby, P. & Key, T. J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170-183 (2008).
74. Tsai, C. J. et al. Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States). Cancer Causes Control 17, 1237-1244 (2006).
75. Gupta, D., Rager, K., Attanasio, A., Klemm, W. & Eichner, M. Sex steroid hormones during multiphase pubertal developments. J. Steroid Biochem. 6, 859-868 (1975).
76. Gapstur, S. M. et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol. Biomarkers Prev. 11, 1041-1047 (2002).
77. Lolis, M. S., Bowe, W. P. & Shalita, A. R. Acne and systemic disease. Med. Clin. North Am. 93, 1161-1181 (2009).
78. Udry, J. R., Billy, J. O., Morris, N. M., Groff, T. R. & Raj, M. H. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil. Steril. 43, 90-94 (1985).
79. Knussmann, R., Christiansen, K. & Couwenbergs, C. Relations between sex hormone levels and sexual behavior in men. Arch. Sex. Behav. 15, 429-445 (1986).
80. Mantzoros, C. S., Georgiadis, E. I. & Trichopoulos, D. Contribution of dihydrotestosterone to male sexual behaviour. BMJ 310, 1289-1291 (1995).
81. Herbst, K. L. & Bhasin, S. Testosterone action on skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 7, 271-277 (2004).
82. Giles, G. G. et al. Early growth, adult body size and prostate cancer risk. Int. J. Cancer 103, 241-245 (2003).
83. Lightfoot, N. et al. Medical history, sexual, and maturational factors and prostate cancer risk. Ann. Epidemiol. 14, 655-662 (2004).
84. Sutcliffe, S., Giovannucci, E., Isaacs, W. B., Willett, W. C. & Platz, E. A. Acne and risk of prostate cancer. Int. J. Cancer 121, 2688-2692 (2007).
85. Oishi, K. et al. A case-control study of prostatic cancer in Kyoto, Japan: sexual risk factors. Prostate 17, 269-279 (1990).
86. Hsieh, C. C. et al. Risk factors for prostate cancer: a case-control study in Greece. Int. J. Cancer 80, 699-703 (1999).
87. Giles, G. G. et al. Sexual factors and prostate cancer. BJU Int. 92, 211-216 (2003).
88. Leitzmann, M. F., Platz, E. A., Stampfer, M. J., Willett, W. C. & Giovannucci, E. Ejaculation frequency and subsequent risk of prostate cancer. JAMA 291, 1578-1586 (2004).
89. Isaacs, J. T. Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate 4, 351-366 (1983).
90. Liu, X., Rybicki, B. A., Casey, G. & Witte, J. S. Relationship between body size and prostate cancer in a sibling based case-control study. J. Urol. 174, 2169-2173 (2005).
91. Dal Maso, L. et al. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br. J. Cancer 90, 2176-2180 (2004).
92. Barba, M. et al. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study. Urology 72, 183-187 (2008).
93. Jeffreys, M., Smith, G. D., Martin, R. M., Frankel, S. & Gunnell, D. Childhood body mass index and later cancer risk: a 50-year follow-up of the Boyd Orr study. Int. J. Cancer 112, 348-351 (2004).
94. Ilic, M., Vlajinac, H. & Marinkovic, J. Case-control study of risk factors for prostate cancer. Br. J. Cancer 74, 1682-1686 (1996).
95. Robinson, W. R., Poole, C. & Godley, P. A. Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control 19, 793-803 (2008).
96. Cox, B., Sneyd, M. J., Paul, C. & Skegg, D. C. Risk factors for prostate cancer: a national case-control study. Int. J. Cancer 119, 1690-1694 (2006).
97. Bassett, J. K. et al. Weight change and prostate cancer incidence and mortality. Int. J. Cancer 131, 1711-1719 (2012).
98. Robinson, W. R., Stevens, J., Gammon, M. D. & John, E. M. Obesity before age 30 years and risk of advanced prostate cancer. Am. J. Epidemiol. 161, 1107-1114 (2005).
99. Freedland, S. J. & Platz, E. A. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol. Rev. 29, 88-97 (2007).
100. Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A. & Willett, W. C. Height, body weight, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 6, 557-563 (1997).
101. Rhoads, G. G. & Kagan, A. The relation of coronary disease, stroke, and mortality to weight in youth and in middle age. Lancet 1, 492-495 (1983).
102. Casey, V. A. et al. Long-term memory of body weight and past weight satisfaction: a longitudinal follow-up study. Am. J. Clin. Nutr. 53, 1493-1498 (1991).
103. Tamakoshi, K. et al. The accuracy of long-term recall of past body weight in Japanese adult men. Int. J. Obes Relat. Metab. Disord. 27, 247-252 (2003).
104. Casey, V. A. et al. Accuracy of recall by middle-aged participants in a longitudinal study of their body size and indices of maturation earlier in life. Ann. Hum. Biol. 18, 155-166 (1991).
105. Gilger, J. W., Geary, D. C. & Eisele, L. M. Reliability and validity of retrospective self-reports of the age of pubertal onset using twin, sibling, and college student data. Adolescence 26, 41-53 (1991).
106. Mishina, T., Watanabe, H., Araki, H. & Nakao, M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 6, 423-436 (1985).
107. Fincham, S. M., Hill, G. B., Hanson, J. & Wijayasinghe, C. Epidemiology of prostatic cancer: a case-control study. Prostate 17, 189-206 (1990).
108. Hayes, R. B. et al. Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur. J. Cancer Prev. 1, 239-245 (1992).
109. Habel, L. A., Van Den Eeden, S. K. & Friedman, G. D. Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. Prostate 43, 136-143 (2000).
110. Rosenblatt, K. A., Wicklund, K. G. & Stanford, J. L. Sexual factors and the risk of prostate cancer. Am. J. Epidemiol. 153, 1152-1158 (2001).
111. Sutcliffe, S. Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol. 6, 1289-1311 (2010).
112. Dennis, L. K. & Dawson, D. V. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13, 72-79 (2002).
113. Larke, N. Male circumcision, HIV and sexually transmitted infections: a review. Br. J. Nurs. 19, 629-634 (2010).
114. Wynder, E. L., Mabuchi, K. & Whitmore, W. F. Jr. Epidemiology of cancer of the prostate. Cancer 28, 344-360 (1971).
115. Mandel, J. S. & Schuman, L. M. Sexual factors and prostatic cancer: results from a case-control study. J. Gerontol. 42, 259-264 (1987).
116. Wright, J. L., Lin, D. W. & Stanford, J. L. Circumcision and the risk of prostate cancer. Cancer 118, 4437-4443 (2012).
117. Ewings, P. & Bowie, C. A case-control study of cancer of the prostate in Somerset and east Devon. Br. J. Cancer 74, 661-666 (1996).
118. Ross, R. K., Shimizu, H., Paganini-Hill, A., Honda, G. & Henderson, B. E. Case-control studies of prostate cancer in blacks and whites in southern California. J. Natl Cancer Inst. 78, 869-874 (1987).
119. Ravich, A. & Ravich, R. A. Prophylaxis of cancer of the prostate, penis, and cervix by circumcision. N. Y. State J. Med. 51, 1519-1520 (1951).
120. Apt, A. Circumcision and prostatic cancer. Acta Med. Scand. 178, 493-504 (1965).
121. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. (US Department of Health and Human Services, 2011).
122. Urbanek, C. et al. Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer 11, 233 (2011).
123. Barykova, Y. A. et al. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget 2, 289-297 (2011).
124. Hrbacek, J. et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer 11, 53 (2011).
125. Whittemore, A. S., Paffenbarger, R. S. Jr., Anderson, K. & Lee, J. E. Early precursors of site-specific cancers in college men and women. J. Natl Cancer Inst. 74, 43-51 (1985).
126. Shannon, B. A., Garrett, K. L. & Cohen, R. J. Links between Propionibacterium acnes and prostate cancer. Future Oncol. 2, 225-232 (2006).
127. Sfanos, K. S. et al. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 68, 306-320 (2008).
128. Chambers, C. V. et al. Microflora of the urethra in adolescent boys: relationships to sexual activity and nongonococcal urethritis. J. Pediatr. 110, 314-321 (1987).
129. International Agency for Research on Cancer. IARC Handbook of Cancer Prevention Volume 6: Weight control and physical activity. (WHO, 2002).
130. Villeneuve, P. J., Johnson, K. C., Kreiger, N. & Mao, Y. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 10, 355-367 (1999).
131. Lacey, J. V. Jr et al. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Int. J. Epidemiol. 30, 341-349 (2001).
132. Friedenreich, C. M., McGregor, S. E., Courneya, K. S., Angyalfi, S. J. & Elliott, F. G. Case-control study of lifetime total physical activity and prostate cancer risk. Am. J. Epidemiol. 159, 740-749 (2004).
133. Pierotti, B. et al. Lifetime physical activity and prostate cancer risk. Int. J. Cancer 114, 639-642 (2005).
134. Littman, A. J., Kristal, A. R. & White, E. Recreational physical activity and prostate cancer risk (United States). Cancer Causes Control 17, 831-841 (2006).
135. Darlington, G. A., Kreiger, N., Lightfoot, N., Purdham, J. & Sass-Kortsak, A. Prostate cancer risk and diet, recreational physical activity and cigarette smoking. Chronic Dis. Can. 27, 145-153 (2007).
136. Wiklund, F. et al. Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. Eur. J. Epidemiol. 23, 739-746 (2008).
137. Krishnadasan, A., Kennedy, N., Zhao, Y., Morgenstern, H. & Ritz, B. Nested case-control study of occupational physical activity and prostate cancer among workers using a job exposure matrix. Cancer Causes Control 19, 107-114 (2008).
138. Moore, S. C. et al. Age-specific physical activity and prostate cancer risk among white men and black men. Cancer 115, 5060-5070 (2009).
139. Liu, Y. et al. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur. Urol. 60, 1029-1044 (2011).
140. Kriska, A. M. et al. The assessment of historical physical activity and its relation to adult bone parameters. Am. J. Epidemiol. 127, 1053-1063 (1988).
141. Chasan-Taber, L. et al. Reproducibility of a self-administered lifetime physical activity questionnaire among female college alumnae. Am. J. Epidemiol. 155, 282-289 (2002).
142. Friedenreich, C. M., Courneya, K. S. & Bryant, H. E. The lifetime total physical activity questionnaire: development and reliability. Med. Sci. Sports Exerc. 30, 266-274 (1998).
143. Slattery, M. L., Schumacher, M. C., West, D. W., Robison, L. M. & French, T. K. Food-consumption trends between adolescent and adult years and subsequent risk of prostate cancer. Am. J. Clin. Nutr. 52, 752-757 (1990).
144. Torfadottir, J. E. et al. Milk intake in early life and risk of advanced prostate cancer. Am. J. Epidemiol. 175, 144-153 (2012).
145. Torfadottir, J. E. et al. Rye bread consumption in early life and reduced risk of advanced prostate cancer. Cancer Causes Control 23, 941-950 (2012).
146. Chavarro, J. E. et al. Validity of adolescent diet recall 48 years later. Am. J. Epidemiol. 170, 1563-1570 (2009).
147. Mills, P. K., Beeson, W. L., Phillips, R. L. & Fraser, G. E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64, 598-604 (1989).
148. Dirx, M. J., van den Brandt, P. A., Goldbohm, R. A. & Lumey, L. H. Energy restriction in childhood and adolescence and risk of prostate cancer: results from the Netherlands Cohort Study. Am. J. Epidemiol. 154, 530-537 (2001).
149. Luscombe, C. J. et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 358, 641-642 (2001).
150. Bodiwala, D. et al. Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett. 192, 145-149 (2003).
151. Gilbert, R. et al. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int. J. Cancer 125, 1414-1423 (2009).
152. John, E. M., Schwartz, G. G., Koo, J., Van Den Berg, D. & Ingles, S. A. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 65, 5470-5479 (2005).
153. Nair-Shalliker, V. et al. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. Int J Cancer 131, 2204-2205 (2011).
154. Freedman, D. M., Dosemeci, M. & McGlynn, K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup. Environ. Med. 59, 257-262 (2002).
155. John, E. M., Koo, J. & Schwartz, G. G. Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol. Biomarkers Prev. 16, 1283-1286 (2007).
156. Must, A., Phillips, S. M. & Naumova, E. N. Occurrence and timing of childhood overweight and mortality: findings from the Third Harvard Growth Study. J. Pediatr. 160, 743-750 (2012).
157. Mathewson, F. A., Brereton, C. C., Keltie, W. A. & Paul, G. I. The Univeristy of Manitoba follow-up study: a prospective investigation of cardiovascular disease. I. General description-mortality and incidence of coronary heart disease. Can. Med. Assoc. J. 92, 947-953 (1965).
158. Angelsen, A., Falkmer, S., Sandvik, A. K. & Waldum, H. L. Pre- and postnatal testosterone administration induces proliferative epithelial lesions with neuroendocrine differentiation in the dorsal lobe of the rat prostate. Prostate 40, 65-75 (1999).
159. Suttie, A. et al. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol. Pathol. 31, 31-38 (2003).
160. Suttie, A. W. et al. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse. Toxicol. Pathol. 33, 386-397 (2005).
161. Berkey, C. S. et al. Prospective study of adolescent alcohol consumption and risk of benign breast disease in young women. Pediatrics 125, e1081-e1087 (2010).
162. Nakayama, M. et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163, 923-933 (2003).
163. Humphrey, P. A. in Prostate Pathology 182-217 (American Society for Clinical Pathology, 2003).
164. Hurst, R. et al. Selenium and prostate cancer: systematic review and meta-analysis. Am. J. Clin. Nutr. 96, 111-122 (2012).
165. Huncharek, M., Muscat, J. & Kupelnick, B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr. Cancer 60, 421-441 (2008).
166. Wei, M. Y. & Giovannucci, E. L. Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era. J. Oncol. 2012, 271063 (2012).
167. Alexander, D. D., Mink, P. J., Cushing, C. A. & Sceurman, B. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. Nutr. J. 9, 50 (2010).
168. Simon, J. A., Chen, Y. H. & Bent, S. The relation of α-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis. Am J. Clin. Nutr. 89, 1558S-1564S (2009).